Probably—but it is still a prediction, not a proven outcome. Eli Lilly has fast-growing businesses in immunology, oncology and neuroscience, while its research pipeline adds further options. Yet Mounjaro and Zepbound supplied 65% of revenue in the first half of 2026, so any “next growth engine” must become very large to materially reduce that dependence.
The short answer: a credible opportunity, not a demonstrated replacement
Eli Lilly’s results show that growth beyond weight-loss medicines is already appearing, especially in products grouped under immunology, oncology and neuroscience. In the company’s second-quarter 2026 earnings slides, revenue from Key Products in those three areas grew 121% year over year. The same quarter produced $15.7 billion in total Key Product revenue, up 76%.
As an Amazon Associate I earn from qualifying purchases.
Those figures are encouraging, but they combine several medicines and come from a smaller base than Lilly’s incretin franchise. They do not show that one non-weight-loss drug grew 121%, nor that the rate can persist. The practical question for an LLY investor is whether these businesses can add enough absolute revenue, profit and durability to offset the current concentration in Mounjaro and Zepbound.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Management remains highly optimistic. In the August 6, 2026 results release, chief executive David A. Ricks said, “Lilly’s momentum continues, as we delivered 48% revenue growth and raised our full-year guidance.” He also described retatrutide, new manufacturing capacity and business-development assets as reasons the company’s future “has never been brighter.” Those are management views and guidance, not independent proof of future returns.
#1 Best Overall
How dependent is Lilly on Mounjaro and Zepbound?
Lilly’s Form 10-Q for the six months ended June 30, 2026, reported that Mounjaro and Zepbound together represented 65% of total company revenue. That is the baseline against which diversification should be judged: a new business can be growing rapidly and still be too small to change the company’s overall risk profile.
| Measure | Reported result | What it means for the thesis |
|---|---|---|
| Total revenue growth, Q2 2026 | 48% year over year | Shows exceptional current momentum, but not how much came from incretin medicines. |
| Mounjaro revenue, Q2 2026 | $9.9 billion worldwide, up 91% year over year | The principal growth engine remains extremely large and fast-growing. |
| Zepbound revenue, Q2 2026 | $4.9 billion in the United States, up 44% year over year | Confirms substantial demand in the U.S. weight-management market. |
| Mounjaro plus Zepbound share | 65% of revenue for the six months ended June 30, 2026 | A high concentration bar for any diversification strategy. |
| 2025 full-year revenue | $65.179 billion, up 45% from 2024 | Provides the larger company scale against which newer franchises must be measured. |
| Key Products, Q2 2026 | $15.7 billion, up 76% year over year | Includes multiple products and therapeutic areas, not only weight-loss medicines. |
Lilly also said lower realized prices partially offset demand growth in the quarter. Revenue therefore reflects both the number of doses sold and the net price after discounts, rebates and other adjustments. A high unit-growth rate does not automatically translate into the same rate of net-sales or profit growth.
Which commercial businesses could grow beyond weight loss?
Neuroscience and Alzheimer’s disease
Kisunla gives Lilly a marketed Alzheimer’s product outside the incretin category. Alzheimer’s is a difficult commercial and scientific area: diagnosis, specialist capacity, treatment eligibility, monitoring requirements and payer decisions all affect adoption. A marketed product is evidence of commercial presence, not a guarantee of a mass-market outcome.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Lilly’s July 9, 2026 announcement about the Alzheimer’s Association International Conference said the company planned 16 abstracts for AAIC 2026, including three oral presentations. The program included analyses of Kisunla and the P-tau217 blood test. Conference presentations can expand scientific evidence and awareness, but the announcement itself did not establish the results of those studies, regulatory status for a blood test, or a revenue forecast.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
The company also lists continuing donanemab development beyond the currently marketed population. Investors should separate an approved indication from a label-expansion study: the latter still depends on clinical data, regulatory review and eventual payer and physician adoption.
Oncology
Lilly’s commercial oncology portfolio includes Inluriyo and Jaypirca. Their use is tied to particular cancer populations described in Lilly’s annual filing, so neither should be treated as a medicine for every patient with breast cancer or leukemia. Current labels, geography and line-of-therapy requirements matter when estimating eligible patients.
Oncology can provide diversification because several products and indications may contribute over time. It also brings intense competition, changing treatment standards and evidence requirements. Lilly’s filing describes additional oncology development work, but the existence of candidates does not establish approval, launch timing or commercial scale.
Immunology
Omvoh and Ebglyss are among the products Lilly identifies in its commercial materials outside weight loss. Their contribution supports the case that Lilly is building more than one therapeutic franchise. However, product-level trajectories are more informative than an aggregate growth percentage: investors need sales by medicine, indication expansion, access conditions and competitive positioning before deciding whether immunology can become a major earnings pillar.
What the 121% non-incretin growth figure does—and does not—show
The 121% year-over-year increase applies to Key Product revenue in immunology, oncology and neuroscience combined in Q2 2026. It is a company-reported aggregate, and the underlying products do not necessarily share the same growth rate. The combined figure can also be amplified by a small starting base, a recent launch or a newly added indication.
A better test is to track four layers at once:
- Absolute sales: how many dollars the group adds, not only its percentage rate.
- Individual-product contribution: which medicines are responsible for the increase and whether growth is broad or concentrated in one launch.
- Persistence: whether growth continues after the first several quarters of launch or comparison against a low base.
- Economic quality: whether net pricing, manufacturing costs and development spending allow revenue growth to become durable operating profit.
Without those details, 121% is an important signal of momentum but not proof that the group can replace the incretin franchise.
How the pipeline changes the opportunity
Lilly’s official clinical-development pipeline contains assets at multiple stages. Retatrutide appears in several cardiometabolic programs, and donanemab has ongoing Alzheimer’s development work. Other candidates span additional diseases and mechanisms.
Retatrutide could extend Lilly’s cardiometabolic leadership, but it would not by itself diversify the company away from incretin-related exposure. It may enlarge the same broad metabolic opportunity while introducing new clinical, manufacturing, pricing and competitive questions. A pipeline asset should therefore be classified separately from a non-incretin growth engine.
Rank #4
For every investigational medicine, ask three separate questions:
- Clinical probability: Does the trial produce results that support approval and a useful label?
- Timing: When could a regulatory decision and commercial launch occur, if development succeeds?
- Economics: How many patients could realistically receive it, at what net price and under what competitive conditions?
Pipeline breadth creates optionality because one successful program can become meaningful. It also creates uncertainty because most candidates face scientific, regulatory, timing and commercial risks before reaching scale. Pipeline assets should never be added to current product revenue in an investment calculation.
A practical framework for testing the “second growth engine” prediction
1. Compare scale with the 65% concentration
Start with reported sales for Mounjaro and Zepbound, then compare the absolute revenue of all non-incretin products. The issue is not whether another category grows faster in percentage terms; it is whether that category can become large enough to reduce the company’s dependence on two medicines that already provide most first-half revenue.
Recommended Free Tools
2. Separate demand from net price
Track prescriptions, units, gross sales and realized net sales where Lilly discloses them. Lilly’s Q2 commentary specifically noted that lower realized prices partly offset demand growth. Rebates, discounts and access arrangements can change the economic value of volume growth.
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
3. Break apart aggregate categories
Do not treat the 121% immunology-oncology-neuroscience figure as a single product forecast. Review each named medicine’s sales, launch quarter, indication and geography. A diversified portfolio should show multiple products contributing, rather than one new medicine carrying the entire category.
4. Distinguish marketed products from candidates
Kisunla, Inluriyo, Jaypirca and Omvoh are commercial products described in Lilly filings and materials. Retatrutide, additional donanemab studies and other pipeline programs are development projects. They belong in different columns of an analysis because approval, uptake and revenue are not interchangeable stages.
5. Check execution constraints
Monitor regulatory decisions, clinical readouts, manufacturing capacity, launch execution, payer access and competitive responses. Lilly has said that new manufacturing capacity is coming online, but capacity announcements do not by themselves prove that supply will meet demand at an attractive margin.
Free tools Windows power users keep installed
One-click scans. No signup required.
Risks that could keep the opportunity from becoming “massive”
- Incretin concentration: If Mounjaro and Zepbound continue to grow much faster than other products, their share of company revenue may remain high even while diversification businesses expand.
- Price pressure: Lower realized prices, rebates or broader access concessions can reduce the revenue and profit produced by each prescription.
- Small-base effects: Triple-digit growth from a recently launched or small product does not indicate a comparable dollar contribution to the established franchise.
- Clinical and regulatory setbacks: Investigational medicines can fail trials, receive narrower labels, face delays or require additional evidence.
- Adoption friction: Specialist treatment capacity, diagnosis, monitoring, payer rules and physician familiarity can slow uptake, particularly in complex diseases.
- Competition: Rival medicines, new mechanisms and changing treatment guidelines can limit market share or force lower prices.
- Manufacturing and supply: Demand growth is valuable only if Lilly can produce and distribute medicines reliably while controlling cost.
These risks do not invalidate the thesis. They explain why the evidence supports an opportunity rather than a conclusion.
What to monitor in future Lilly reports
- Revenue share from Mounjaro and Zepbound, reported for the latest quarter and year-to-date period.
- Absolute sales and growth for Kisunla, Inluriyo, Jaypirca, Omvoh, Ebglyss and other named Key Products.
- Whether immunology, oncology and neuroscience growth remains broad across products after base effects fade.
- Net-price commentary and any explanation of rebates, discounts or access changes.
- Clinical readouts and regulatory decisions for retatrutide, donanemab studies and other leading candidates.
- Evidence that manufacturing additions are operating on schedule and supporting demand without eroding margins.
- Management guidance changes, while treating guidance as a forecast that can be revised rather than a guarantee.
Growth in Lilly’s business is not the same as a stock return
This analysis concerns the company’s operating prospects, not a price target or individualized investment recommendation. Even if Lilly successfully builds large immunology, oncology and neuroscience franchises, an investor’s return would also depend on the price paid for LLY shares, future earnings expectations, capital allocation, interest rates and market sentiment.
Conversely, strong product growth may not immediately produce a favorable share return if expectations already discount that success. The useful conclusion is narrower: Lilly has identifiable sources of growth beyond weight loss, but the current revenue mix means investors must watch absolute scale, durability and economics before calling them a second massive engine.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Clear out junk files and repair common Windows errors3Fix the driver behind crashes, sound loss and screen glitches
